ALPA62.19

Alpa Laboratories Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersBALPHARMAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹131 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations108.7112.5105.8110.6
Other Income14.923.315.89.6
Total Income123.6135.8121.6120.2
Expenses
+ Cost of Materials Consumed62.970.763.372.8
+ Purchases of Stock-in-Trade5.80.90.20.2
+ Changes in Inventories-0.6-1.52.90.5
+ Employee Benefit Expense13.314.415.816.3
+ Finance Costs0.40.20.30.3
+ Depreciation & Amortisation2.02.22.12.3
+ Other Expenses19.323.120.421.9
Total Expenses102.9110.1104.9114.3
EBITDA8.14.83.3-1.1
EBIT6.22.61.2-3.3
Profit
PBT before Exceptional Items20.725.716.75.9
+ Exceptional Items0.00.0-0.9-0.9
Pretax Income20.725.715.85.0
+ Current Tax3.04.13.02.8
+ Deferred Tax0.92.1-1.3-1.3
Tax Expense3.96.21.71.5
Net Income16.819.514.13.5
+ Net Income — Continuing Ops16.819.514.13.5
+ Other Comprehensive Income0.10.10.00.1
Total Comprehensive Income16.919.714.13.6
Per Share
Basic EPS8.019.346.711.68
Diluted EPS8.019.340.001.44
Other Comprehensive Income — detail
+ Other Comprehensive Income0.1
+ Items NOT to be Reclassified to P&L0.1
+ Tax on Items NOT to be Reclassified-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations8.019.346.711.68
Diluted EPS — Continuing Operations8.019.340.001.44
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit40.742.339.537.1
Gross Margin %37.4337.5737.2833.52
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)20.725.716.75.9
− Exceptional Items (reconciliation)0.00.0-0.9-0.9
Net Income Adj (tax-effected)16.819.514.94.1
EPS Adj8.019.347.091.98
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital21.021.021.021.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.